Hologic Inc (HOLX)
$47.08 0.26 (0.55%)
16:59 EDT HOLX Stock Quote Delayed 15 Minutes
Previous Close $47.08
Market Cap 12.85B
PE Ratio -94.16
Volume (Avg. Vol.) 2.05M
Day's Range 46.93 - 47.42
52-Week Range 37.47 - 49.78
Dividend & Yield N/A (N/A)
HOLX Stock Predictions, Articles, and Hologic Inc News
- From InvestorPlace
- From the Web
Expedia, Alexion and DowDuPont are just some of the stocks to buy to overcome the marketwide lethargy that takes shape this time of year.
The stock charts of MSFT, HOLX and DWDP are positioned to end the week on a trade-worthy foot. Here's what to watch before the weekend.
The stock charts of GE, HOLX and MGM have earned a closer look here as the market's rebound starts to slow. Here's what to watch.
The stock charts of NWL, JNPR and HOLX have earned a closer technical look as the trading week winds down.
The stock charts of KO, HOLX and AMAT look like the safest plays headed into the holiday break. Here's what to know.
You may not have to wait long to see value stocks outperform. Kiplinger and Buckingham see 2018 as the year value stocks make a comeback.
Hologic Inc (NASDAQ:HOLX) is one of the 785 companies in the GICS Health Care sector, and a component of the 164 company Health Care Equipment & Supplies GICS industry group within this sector. HOLX has a market value of $11.1 billion which is in the top 25% of its industry group. The ranking for HOLX by Portfolio Grader places it 83 among the 164 companies in this industry group, which is a below-average position; in the third quartile of the sector with a ranking of 394 among the 785 companies in the sector, and number 2,557 in the nearly 5,000 company Portfolio Grader universe.
Some of the best healthcare stocks can be found outside traditional pharma and biotech plays, and instead in medical devices and tech fields.
From Smarter Analyst
From Analyst Ratings
Needham analyst Michael Matson maintained a Buy rating on Hologic (HOLX – Research Report) on July 8 and set a price target of $52. The company’s shares closed yesterday at $47.81, close to its 52-week high of $49.78. Matson wrote: “FDA’s latest monthly Act (MQSA) statistics were published on 7/1/19. The number of digital breast
The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!